# Central Plains Bancshares, Inc.: financial statements, quarterly

CPBI · Nasdaq · CIK 1979332 · [Financials](/sectors/financials.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/cpbi.md) · [Financials](/companies/cpbi/financials.md) · [Filings](/companies/cpbi/filings.md) · [Insiders](/companies/cpbi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cpbi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $k | [1,551](/filings/0000950170-24-125525.md) | [1,694](/filings/0000950170-25-017946.md) | [1,814 d](/filings/0000950170-25-090434.md) | [1,945](/filings/0000950170-25-107380.md) | [2,091](/filings/0001193125-25-280272.md) | [2,115](/filings/0001193125-26-046679.md) | [2,063 d](/filings/0001193125-26-275962.md) | [2,090](/filings/0001193125-26-346968.md) | [2,200](/filings/0001193125-25-280272.md) | [2,316](/filings/0001193125-26-046679.md) | [2,385 d](/filings/0001193125-26-275962.md) | [2,455](/filings/0001193125-26-346968.md) |
| Income tax | $k | [259](/filings/0000950170-24-125525.md) | [218](/filings/0000950170-25-017946.md) | [168 d](/filings/0000950170-25-090434.md) | [207](/filings/0000950170-25-107380.md) | [205](/filings/0001193125-25-280272.md) | [240](/filings/0001193125-26-046679.md) | [217 d](/filings/0001193125-26-275962.md) | [241](/filings/0001193125-26-346968.md) | [233](/filings/0001193125-25-280272.md) | [300](/filings/0001193125-26-046679.md) | [217 d](/filings/0001193125-26-275962.md) | [357](/filings/0001193125-26-346968.md) |
| Net income | $k | [973](/filings/0000950170-24-125525.md) | [937](/filings/0000950170-25-017946.md) | [903 d](/filings/0000950170-25-090434.md) | [903](/filings/0000950170-25-107380.md) | [952](/filings/0001193125-25-280272.md) | [951](/filings/0001193125-26-046679.md) | [848 d](/filings/0001193125-26-275962.md) | [988](/filings/0001193125-26-346968.md) | [882](/filings/0001193125-25-280272.md) | [1,175](/filings/0001193125-26-046679.md) | [955 d](/filings/0001193125-26-275962.md) | [1,492](/filings/0001193125-26-346968.md) |
| Diluted EPS | $ per share | not reported | [0.31](/filings/0000950170-25-017946.md) | not reported | [0.24](/filings/0000950170-25-107380.md) | [0.25](/filings/0001193125-25-280272.md) | [0.25](/filings/0001193125-26-046679.md) | not reported | [0.26](/filings/0001193125-26-346968.md) | [0.23](/filings/0001193125-25-280272.md) | [0.31](/filings/0001193125-26-046679.md) | not reported | [0.39](/filings/0001193125-26-346968.md) |
| Basic EPS | $ per share | not reported | [0.31](/filings/0000950170-25-017946.md) | not reported | [0.24](/filings/0000950170-25-107380.md) | [0.25](/filings/0001193125-25-280272.md) | [0.25](/filings/0001193125-26-046679.md) | not reported | [0.26](/filings/0001193125-26-346968.md) | [0.23](/filings/0001193125-25-280272.md) | [0.31](/filings/0001193125-26-046679.md) | not reported | [0.39](/filings/0001193125-26-346968.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.4](/filings/0000950170-23-062966.md) | [11.7](/filings/0000950170-24-014584.md) | [11.5](/filings/0000950170-25-090434.md) | [5.5](/filings/0000950170-24-092868.md) | [9.9](/filings/0000950170-24-125525.md) | [6.6](/filings/0000950170-25-017946.md) | [28.7](/filings/0001193125-26-275962.md) | [7.9](/filings/0000950170-25-107380.md) | [8.9](/filings/0001193125-25-280272.md) | [28.1](/filings/0001193125-26-046679.md) | [29.9](/filings/0001193125-26-346968.md) | [34.4](/filings/0001193125-26-346968.md) |
| Total assets | $m | [454](/filings/0000950170-23-062966.md) | [454](/filings/0000950170-24-014584.md) | [463](/filings/0000950170-25-090434.md) | [467](/filings/0000950170-24-092868.md) | [482](/filings/0000950170-24-125525.md) | [484](/filings/0000950170-25-017946.md) | [509](/filings/0001193125-26-275962.md) | [501](/filings/0000950170-25-107380.md) | [510](/filings/0001193125-25-280272.md) | [536](/filings/0001193125-26-046679.md) | [559](/filings/0001193125-26-346968.md) | [562](/filings/0001193125-26-346968.md) |
| Total liabilities | $m | [415](/filings/0000950170-23-062966.md) | [377](/filings/0000950170-24-014584.md) | [385](/filings/0000950170-25-090434.md) | [387](/filings/0000950170-24-092868.md) | [400](/filings/0000950170-24-125525.md) | [403](/filings/0000950170-25-017946.md) | [425](/filings/0001193125-26-275962.md) | [416](/filings/0000950170-25-107380.md) | [424](/filings/0001193125-25-280272.md) | [448](/filings/0001193125-26-046679.md) | [470](/filings/0001193125-26-346968.md) | [472](/filings/0001193125-26-346968.md) |
| Shareholders' equity | $m | [38.5](/filings/0000950170-25-017946.md) | [77.8](/filings/0000950170-25-017946.md) | [78.3](/filings/0001193125-26-275962.md) | [79.2](/filings/0001193125-25-280272.md) | [81.6](/filings/0001193125-26-046679.md) | [81.3](/filings/0001193125-26-046679.md) | [83.3](/filings/0001193125-26-346968.md) | [84.6](/filings/0001193125-26-346968.md) | [86.2](/filings/0001193125-26-046679.md) | [87.8](/filings/0001193125-26-046679.md) | [89.0](/filings/0001193125-26-346968.md) | [90.3](/filings/0001193125-26-346968.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [428 d](/filings/0000950170-24-125525.md) | [2,637 d](/filings/0000950170-25-017946.md) | [1,482 d](/filings/0000950170-25-090434.md) | [505](/filings/0000950170-25-107380.md) | [1,199 d](/filings/0001193125-25-280272.md) | [674 d](/filings/0001193125-26-046679.md) | [2,081 d](/filings/0001193125-26-275962.md) | [(96.0)](/filings/0001193125-26-346968.md) | [1,130 d](/filings/0001193125-25-280272.md) | [2,287 d](/filings/0001193125-26-046679.md) | [3,365 d](/filings/0001193125-26-275962.md) | [(198)](/filings/0001193125-26-346968.md) |
| Capital expenditure | $k | [137 d](/filings/0000950170-24-125525.md) | [349 d](/filings/0000950170-25-017946.md) | [1,748 d](/filings/0000950170-25-090434.md) | [470](/filings/0000950170-25-107380.md) | [2,174 d](/filings/0001193125-25-280272.md) | [2,154 d](/filings/0001193125-26-046679.md) | [2,728 d](/filings/0001193125-26-275962.md) | [670](/filings/0001193125-26-346968.md) | [242 d](/filings/0001193125-25-280272.md) | [60.0 d](/filings/0001193125-26-046679.md) | [(94.0) d](/filings/0001193125-26-275962.md) | [2.0](/filings/0001193125-26-346968.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | [276 d](/filings/0001193125-26-275962.md) | [260](/filings/0001193125-26-346968.md) | [90.0 d](/filings/0001193125-25-280272.md) | [194 d](/filings/0001193125-26-046679.md) | [135 d](/filings/0001193125-26-275962.md) | [296](/filings/0001193125-26-346968.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,058](/filings/0000950170-25-017946.md) | [3,818](/filings/0000950170-25-107380.md) | [3,821](/filings/0001193125-25-280272.md) | [3,841](/filings/0001193125-26-046679.md) | [3,804](/filings/0001193125-26-346968.md) | [3,809](/filings/0001193125-25-280272.md) | [3,809](/filings/0001193125-26-046679.md) | [3,821](/filings/0001193125-26-346968.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,172,236 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346968.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.